StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Oncotelic Therapeutics's total debt was $2.72M at Jun 30, 2025. For fiscal 2024 it was $2.42M, up 37.2% from the year before. The highest annual figure on record is $2.42M in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$2.42M+37.2%
FY2023Dec 31, 2023$1.77M+352.5%
FY2022Dec 31, 2022$390.05K+8.6%
FY2021Dec 31, 2021$359.26K+278.2%
FY2020Dec 31, 2020$95.00K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025$2.72M+25.7%
Q1 FY2025Mar 31, 2025$2.58M+28.1%
Q4 FY2024Dec 31, 2024$2.42M+37.2%
Q3 FY2024Sep 30, 2024$2.38M+62.5%
Q2 FY2024Jun 30, 2024$2.16M+100.0%
Q1 FY2024Mar 31, 2024$2.02M+241.5%
Q4 FY2023Dec 31, 2023$1.77M+352.5%
Q3 FY2023Sep 30, 2023$1.47M+446.3%
Q2 FY2023Jun 30, 2023$1.08M+266.1%
Q1 FY2023Mar 31, 2023$590.05K+64.2%
Q4 FY2022Dec 31, 2022$390.05K+13.6%
Q2 FY2022Jun 30, 2022$268.17K-64.9%
Q1 FY2022Mar 31, 2022$295.05K+110.8%
Q4 FY2021Dec 31, 2021$359.26K+278.2%
Q3 FY2021Sep 30, 2021$343.24K+390.3%
Q2 FY2021Jun 30, 2021$764.88K+992.7%
Q1 FY2021Mar 31, 2021$140.00K–
Q4 FY2020Dec 31, 2020$95.00K–
Q3 FY2020Sep 30, 2020$70.00K–
Q2 FY2020Jun 30, 2020$70.00K–

More Oncotelic Therapeutics figures

See a number that looks wrong?